echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > BeiGene's Guangzhou Biopharmaceutical Base officially commercializes the production of Baizean® and starts dual-base production

    BeiGene's Guangzhou Biopharmaceutical Base officially commercializes the production of Baizean® and starts dual-base production

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 8, innovative pharmaceutical company BeiGene (Nasdaq: BGNE) (06160.


    On-site celebration ceremony

    On-site celebration ceremony

    Previously, BeiGene’s tislelizumab injection was commissioned by Boehringer Ingelheim (China) to produce.


    After the Guangzhou production base officially starts commercial production, the production line of BeiGene and Boehringer Ingelheim (China) will continue to operate, forming a Bazeran® dual-base production model.


    PD-1 ushered in a new era of medical insurance, huge room for market expansion

    On March 1, 2021, the latest version of the National Medical Insurance Drug List was officially launched.


    In response, Dr.


    " Despite fierce competition, the current domestic PD-1 market is still a blue ocean market.


    Guangzhou production base global quality, global supply

    Guangzhou production base global quality, global supply

    It is reported that, in order to achieve the perfection of BeiGene's entire value chain from R&D, production to commercialization, the Guangzhou base of BeiGene has established a set of internationally leading quality management systems, adhering to the construction goal of "global quality, global supply".


    It is understood that BeiGene has invested a total of 2.


    At present, the plant has built a production capacity of 54,000 liters.


    It is worth noting that BeiGene aims to build the Guangzhou production base into an industry-leading China Industry 4.


    Through artificial intelligence, the Guangzhou production base will be built into an industry-leading demonstration base of China's Industry 4.


    In addition, its upcoming third plant has optimized and upgraded the technology of key links such as raw solution production and preparation production, and has begun to adopt multiple large-scale stainless steel reactors, so that the original one-time production line can reduce costs while increasing efficiency.


    According to Michael Garvey (Gao Wei), senior vice president of BeiGene and head of global technical operations: "The localization of key materials is an important goal of BeiGene's Guangzhou production base.


    "The localization of key materials is an important goal of BeiGene's Guangzhou production base.
    In the future, the Guangzhou production base will change from 37% of the original local imported materials to 73%, and realize the domestic sales of shutdown technology, and continue to optimize and upgrade.
    .
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.